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of Parkinson’s disease
Livia De´zsi & La´szlo´ Ve´csei†
5
†MTA-SZTE Neuroscience Research Group, Szeged, Hungary
Introduction: Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by the loss of dopaminergic neurons in the substantia nigra pars
compacta. Non-dopaminergic neurotransmitter systems are also involved in its
pathomechanism. The aim of the treatment is to improve the dopamine-
10deficient state and to alleviate the motor and the non-motor symptoms. Safina-
mide is an a-aminoamide derivative with a combined, dopaminergic and non-
dopaminergic mode of action. Phase III clinical trials with safinamide, as add-on
therapy toadopamineagonist (DAA)and to levodopa (LD) in early andadvanced
stage PD, respectively, demonstrated an improvement of the motor symptoms.
15Areas covered: The review discusses the pharmacokinetic and pharmacody-
namic properties of safinamide and provides an overview of the clinical trials
conducted with safinamide in PD. A literature search was made in PubMed for
safinamide, safinamide pharmacokinetics, PD treatment and monoamine
oxidase-B inhibitors, and in PubMed and on the ClinicalTrials.gov site for
20clinical trials with safinamide in PD.
Expert opinion: The place of safinamide in the therapy of PD is yet to be
determined. However, the authors believe that safinamide is a valuable
drug in the treatment of PD treatment with favorable pharmacokinetic and
side-effect profiles. Data so far suggest that it can be used beneficially as
25add-on therapy both to DAAs in early PD and to LD in the later stages of
the disease.
Keywords: dopaminergic, monoamine oxidase-B inhibitors, non-dopaminergic, Parkinson’s
disease, safinamide
30Expert Opin. Investig. Drugs (2014) Early Online:1-14
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder with a frequency that
increases with age. The cause of the neurodegenerative process in PD is not known;
several mechanisms are involved in its development, including oxidative stress,
35inflammatory changes, proteosomal dysfunction andmitochondrial dysfunction [1-3].
The pathogenetic changes include the loss of dopaminergic neurons in the substantia
nigra (SN) pars compacta and the appearance of Lewy bodies within the pigmented
neurons of the SN. It is presumed that motor symptoms occur at a loss of about
60 -- 80% of the dopaminergic neurons in the SN. Non-dopaminergic neurotrans-
40mitter systems, such as the serotonergic, the cholinergic, the adrenergic and glutama-
tergic, are also involved in the pathomechanism of the disease [4]. Besides the motor
symptoms related to the dopamine-deficient state, non-motor symptoms can occur,
even in the early stages of the disease, and impair the quality of life of the patients [5].
PD symptoms are summarized in Table 1.
45
2. Treatment approaches in PD
The treatments available at present mainly improve the motor symptoms caused by
the dopaminergic loss. This can be achieved by supplying the dopamine precursor
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levodopa (LD) to increase the synthesis of dopamine, by
stimulating the dopamine receptors or by acting on the
50 metabolism of dopamine.AQ2 As a result of the improving under-
standing of the complex pathomechanism of the disease, treat-
ment has recently focused on non-dopaminergic medication
for the treatment of the motor and non-motor symptoms
and for alleviation of the dyskinesia. Effective neuroprotective
55 therapy that is capable of halting the disease progression is not
available [1,6,7].
The gold standard of the symptomatic treatment of the
disease is LD therapy. LD, a dopamine precursor capable of
crossing the blood--brain barrier, is taken up by the dopami-
60 nergic neurons and is decarboxylated to dopamine presynapti-
cally in the basal ganglia. The peripheral metabolism
responsible for the side effects is reduced by a peripheral
decarboxylase inhibitor. In the first few months or years of
LD therapy, a stable improvement of the motor symptoms
65 can be seen. In time, however, the effect of LD wears off a
few hours after LD intake. Later, on and off motor fluctua-
tions occur, related to the fluctuations of the peripheral LD
concentration but not correlated to the medication intake in
the late stages of the disease. The progressive decrease in the
70 number of dopaminergic neurons in the SN results in an
inability of the striatum to buffer the variability in the brain
dopamine concentrations caused by a short-acting dopami-
nergic agent. Oral substitution therapy is considered to cause
a pulsatile stimulation of the dopamine receptors, which in
75 turn is considered to underlie the development of motor fluc-
tuations and LD-induced dyskinesia (LID). A continuous
stimulation of the dopaminergic receptors presumably causes
less fluctuation and dyskinesia [8,9]. The dopamine agonists
(DAAs) have longer half-lives than that of LD but provide
80 less symptomatic effect. The catechol-O-methyl transferase
(COMT) inhibitors and the monoamine oxidase (MAO)
inhibitors are dopaminergic agents which inhibit the
dopamine metabolizing enzymes. The COMT inhibitors
increase the bioavailability and the half-life of LD and reduce
85the fluctuations of plasma LD. COMT inhibitors are recom-
mended for patients who exhibit the wearing-off phenome-
non [5], as they improve and may also prevent the onset of
wearing-off. In the STRIDE-PD study, the addition of the
COMT inhibitor entacapone to LD resulted in earlier and
90more dyskinesia as compared with LD/carbidopa alone [10].
Although LD has a short half-life, in the early stages of
disease, the presynaptic terminals are capable of storing dopa-
mine and releasing it in a physiological manner. In advanced
disease stages, the dopamine release becomes synchronous
95with the peripheral LD bioavailability and plasma levels and
leads to a pulsatile stimulation presumably underlying motor
complications. The LD/carbidopa intraintestinal gel (LCIG)
therapy bypasses the gastric emptying, provides a continuous
LD delivery and a smoother plasma LD level with less
100fluctuations [11-13]. The coefficient of variation for the plasma
concentration of LD is decreased by LCIG therapy as com-
pared with oral therapy [11]. Dyskinesias are presumably
diminished as a result of an effect on the central therapeutic
window and not by a reduction of the LD concentration,
105since the daily total dose is not reduced as compared with
the previous oral dose [14]. Clinical trials have shown the effi-
cacy of LCIG therapy in reducing dyskinesias, motor fluctua-
tions [15] and off-time [16-21]. Improvements were revealed in
gait disorder [22,23] and some of the non-motor features of
110PD, such as sleep, fatigue, attention, memory and cardiovas-
cular, gastrointestinal and urinary functions [17,22,23]. Non-
motor symptoms, such as neuropsychiatric symptoms, sleep
disturbances, autonomic symptoms and sensory symptoms,
can occur at any stage of the disease and affect the quality of
115life. The role of dopaminergic pathology in the development
of the non-motor symptoms has been revealed [24]. Some of
the non-motor symptoms, such as depression, anhedonia,
Box 1. Drug summary.
Drug name Safinamide
Phase Pre-registration
Indication Parkinson’s disease
Pharmacology description Monoamine oxidase B inhibitor
Route of administration Oral
Chemical structure
O O F
O
O
NH2
N
H
S
OH
CH3
CH3
Pivotal trial(s) [69-73,75-83]
Pharmaprojects -- copyright to Citeline Drug Intelligence (an Informa business). Readers are referred to Pipeline (http://informa-pipeline.citeline.com) and
Citeline (http://informa.citeline.com).
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panic attacks related to off periods, restless legs syndrome, uri-
nary urgency, nocturia, erectile impotence, constipation,
120 fatigue and pain related to PD, are improved by the dopami-
nergic therapy, although most of the non-motor symptoms
are unresponsive, exacerbated or induced by PD therapy [25].
The pulsatile dopaminergic stimulation is presumed to be
responsible for the development of non-motor fluctuations,
125 and a continuous dopaminergic stimulation might improve
non-motor fluctuations [26].
Other drugs used in the treatment of PD are amantadine,
which is valuable in the treatment of LID, and anticholiner-
gics, which are beneficial in the treatment of PD-related
130 tremor, but whose use is limited by their side effects [7].
3. MAO-B inhibitors
MAO-B is a key enzyme in the metabolism of dopamine in
the brain. MAO-B inhibitors can be used as monotherapy in
the earlier stages of the disease or as add-on therapy to LD in
135the more advanced stages. There is evidence of the role of a
mitochondrial dysfunction and oxidative stress in the patho-
mechanism of genetic and sporadic forms of PD.
A deficiency of complex I of the mitochondrial electron
transport chain has been revealed in PD. The mitochondrial
140dysfunction is accompanied by the oxidative stress caused by
reactive metabolites of dopamine and alterations in the levels
of glutathione and iron in the SN [27]. The action of MAO-B
is central to the processes involved in oxidative stress and
oxidative damage in PD. MAO-B activates 1-methyl-4-
145phenyl-1,2,3,6-tetrahydropyridine (MPTP) to MPP+, enzy-
matically converts dopamine to hydrogen peroxide and
activates other potential toxins, such as isoquinolines and
b-carbolines. In animal models, MAO-B inhibitors prevent
the formation of free radicals and prevent the oxidation of
150MPTP to MPP+ and thereby its neurotoxic effect, but no
disease-modifying effect has been demonstrated for these
compounds to date [28,29]. MAO-B inhibitors may protect
against the generation of free radicals formed from the oxida-
tion of dopamine. AQ3Selegiline may increase neurotrophic
155factor activity and may upregulate molecules which protect
against oxidative stress and exerts an anti-apoptotic role,
such as glutathione, superoxide dismutase, catalase and
B-cell lymphoma-2 protein [30-32].
The selective irreversible MAO-B inhibitors selegiline and
160rasagiline reduce LD breakdown. A recent study evaluated
the effect of long-term MAO-B inhibitor treatment with sele-
giline or rasagiline on MAO-A activity. Plasma samples were
taken from PD patients on MAO-B inhibitor therapy, from
PD patients without MAO-B inhibitor treatment and from
165healthy controls. A 70% reduction in MAO-A activity was
detected ex vivo in PD patients on MAO-B inhibitor therapy
as compared with the other two groups. No difference was
detected between PD patients taking selegiline and rasagiline.
The effect of selegiline on MAO-A activity in vitro was also
170evaluated by incubating human control standardized plasma
samples with selegiline; the IC50 of selegiline was determined
as 44 µM for MAO-A. The results were partially explained by
pharmacokinetic considerations. About 4 h after the last med-
ication intake, the plasma concentrations of selegiline and
175rasagiline were high enough to inhibit MAO-A activity.
Long-term treatment with selegiline has previously been
revealed to increase its t1/2 and keep the concentration in a
range high enough to inhibit MAO-A. The loss of specificity
for MAO-B at higher concentrations and the inhibition of
180both isoenzymes may affect both the peripheral and the brain
MAO. This results in a reduced breakdown of the neurotrans-
mitter amines and might also reduce the synthesis of reactive
oxygen species and other toxic compounds, but the role of the
MAO-B/MAO-A interaction in the pathomechanism of PD
185and the possible neuroprotective effect of MAO-B inhibitors
necessitate further investigations [33].
A large, multicenter, randomized, double-blind, placebo-
controlled trial (DATATOP) proved that selegiline delayed
the need for LD therapy in early PD [34], suggesting a
Table 1. Symptoms of Parkinson’s disease.
Motor symptoms
Bradykinesia/akinesia
Hypokinesia
Tremor
Postural instability
Gait disorder
Non-motor symptoms
Neuropsychiatric symptoms
Psychosis
Hallucinations
Delusions/illusions
Depression
Apathy
Fatigue
Anxiety
Cognitive impairment/dementia
Sleep disorders
REM sleep behavior disorder
RLS
Vivid dreaming
Insomnia
Excessive daytime somnolence
Autonomic symptoms
Drooling
Increased sweating
Gastrointestinal dysfunction
Delayed gastric emptying
Constipation
Bladder dysfunction
Urgency
Frequency
Orthostatic hypotension
Sexual dysfunction
Sensory symptoms
Anosmia
Pain
Paresthesia
REM: Rapid eye movement, RLS: Restless legs syndrome.
Safinamide
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190 neuroprotective effect. The post-hoc analysis revealed the
symptomatic effects of selegiline responsible for some of the
beneficial effects and the long-term follow up of the patients
showed that selegiline does not stop the disease progression [1].
The delayed start studies TEMPO and ADAGIO (a random-
195 ized, double-blind, placebo-controlled, delayed-start study to
assess rasagiline as a disease modifying therapy in Parkinson’s
disease) showed that an early initiation of rasagiline therapy
for early stage PD patients had a beneficial effect on the motor
symptoms, which was preserved during the long-term follow
200 up. In the ADAGIO study, patients were randomized to
1 or 2 mg/day of rasagiline or placebo for 9 months. In the
second part of the study, all patients were treated with active
medication for another 9 months. Patients originally random-
ized to rasagiline 1 mg/day demonstrated less progression of
205 the clinical disability than those randomized to rasagiline after
a delay of 9 months. The benefit was significant for the
1 mg/day dose but not for the 2 m/day dose [35-37].
In the LARGO and PRESTO trials for advanced-stage
disease, the patients who received rasagiline exhibited a reduc-
210 tion of the off time, and significant improvements in the activ-
ities of daily living (ADL), and the motor subscores of the
Unified Parkinson’s Disease Rating Scale (UPDRS) and in
the clinical global impression (CGI) scale score. A reduction
of the daily dose of LD could also be achieved [38-40]. In a trial
215 on early PD patients, rasagiline monotherapy provided bene-
fits in the treatment of some of the non-motor symptoms [41].
A meta-analysis of theMedline and the Cochrane Library data-
base showed that rasagiline as monotherapy reduces the motor
scores in early PD, whereas as add-on therapy to LD, it
220 reduces the off time in the more advanced stages of the
disease [42].
4. Safinamide
Safinamide ((S)-(+)-2-[4-(fluorobenzyl) oxybenzyl]aminopro-
pan amide methanesulfonate) is a water-soluble enantiomeric
225 a-aminoamide derivative with a combined dopaminergic and
non-dopaminergic mode of action (Box 1, for the chemical
structure). It has been developed as antiepileptic medication.
Milacemide was first shown to exhibit weak anticonvulsant
activity and inhibition of MAO-A and -B [43-45]. New a-
230 aminoamides have been developed, among which safinamide
has been further investigated. Safinamide displays MAO-B
inhibitory activity and a voltage-sensitive channel-blocking
activity; its neuroprotective and neurorescuing properties
have also been investigated. It can be used as add-on treat-
235 ment to LD or a DAA and can improve motor symp-
toms [46,47] and some of the non-motor symptoms of
PD [48]. Safinamide has completed the Phase III development
program as add-on therapy to DAAs and to LD in patients
with early and mid-to-late stage PD, respectively, and its ben-
240 eficial effect on the motor symptoms of PD has been
confirmed [49]. Table 2 highlights the place of safinamide in
the therapeutic spectrum of PD and Table 3 presents some
of the clinical trials conducted with safinamide in PD
patients.
245
5. Pharmacokinetics of safinamide
Orally administered safinamide displays favorable pharmaco-
kinetic properties, which are linearly and proportionally
related to the administered dose [50]. The absorption is com-
plete and reliable and is not appreciably influenced by food.
250The absolute bioavailability is high, at 95%. The pharmacoki-
netics is dose-proportional across the therapeutic dose range,
with low intersubject variability. In a study of the pharmaco-
kinetics of safinamide, administered as a single dose of
400 mg [14C] safinamide methanesulfonate to healthy volun-
255teers, maximum concentration was achieved at 1 h for the
parent drug, at 7 h for the plasma and at 1.5 h for the
whole-blood [14C] radioactivity [51]. Its extravascular distribu-
tion is extensive, corresponding to the high lipophilicity. The
plasma protein binding (92%) is apparently lower than the
260extravascular tissue binding [50,52]. Safinamide reaches high
concentrations in the CNS [47].
The biotransformation of safinamide is considerable.
About 1.5 and 7% is excreted in unchanged form in the feces
and urine, respectively [52], which is indicative of the practi-
265cally complete absorption of the drug and very little biliary
excretion. The metabolism of safinamide has two principal
routes. One metabolic route leads to a carboxylic acid metab-
olite (NW-1689) and presumably involves several enzymes,
such as CYP enzymes, MAO-A and the aldehyde dehydrogen-
270ases. A CYP3A4 inhibitor (troleandromycin) exerted only a
minimal effect on the clearance of safinamide in vitro. An
investigation of the effects of another CYP3A4 inhibitor,
ketoconazole, on the metabolic clearance of safinamide in
healthy individuals in a monocentric, open-label, randomized,
275two-period crossover clinical trial showed that the CYP3A4--
mediated metabolism did not significantly contribute to the
metabolic clearance of safinamide in vivo [53]. The results
also revealed that safinamide can be coadministered with
potent CYP3A4 inhibitors without a requirement for dose
280adjustment. The other metabolic route is the direct amide
hydrolysis of safinamide by amidases, leading to the metabo-
lite safinamide acid (NW-1153). In vivo animal studies on
rats, and in vitro studies on rat and human hepatocytes, sug-
gested that NW-1153 is not a metabolic end product, but
285an intermediate converted to NW-1689.
AQ4The main circulating plasma metabolite of safinamide is
NW-1689, which undergoes glucuronidation to become
NW-1689 acyl glucuronide. The deaminated acid and the
N-dealkylated acid have been identified as major metabo-
290lites in the plasma and urine. Other urinary metabolites
identified in a more recent study are the b-glucuronide of
the N-dealkylated acid, monohydroxy safinamide and
minor urinary metabolites such as the glycine conjugate of
the N-dealkylated acid and 2-(4-hydroxybenzylamino)
295propanamide [51].
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AQ5 The systemic clearance of safinamide is low and its terminal
half-life is about 26 h [54]. In the case of the administration of
radioactively labeled safinamide, the terminal half-life was
22 h for the unchanged drug and 80 h for the radioactivity.
300 This permits a once-daily administration. A steady-state
concentration is achieved on day 5 of the once-daily dosing
treatment regimen [51].
Safinamide has proved to be safe and well tolerated. The
vital signs and the biochemical analysis of the blood and urine
305 showed no differences as compared with placebo. No differ-
ence in the pressor response to intravenous administration
of safinamide was encountered in healthy volunteers relative
to placebo administration [55,56].
6. Pharmacodynamics of safinamide
310 The precise mechanism through which safinamide improves
the symptoms of PD is uncertain (Figure 1, for the effect of
safinamide in PD). As mentioned earlier, safinamide has a
combined dopaminergic and non-dopaminergic mechanism
of action, including the selective and reversible inhibition of
315 MAO-B, activity-dependent sodium channel antagonism
and inhibition of glutamate release in vitro. The dopaminergic
mode of action is through potent and highly selective
reversible MAO-B inhibition, thereby enhancing the brain
dopamine concentration [47,57].
320 The selectivity of safinamide for MAO-B has been shown
to be 1000 times higher as compared with placebo. The selec-
tivity of MAO-B over MAO-A is greater than in the cases of
selegiline and rasagiline [47,50,52,58-60]. In the event of
unspecific MAO inhibition, dietary amines enter the circula-
325tion, induce noradrenaline release from peripheral adrenergic
neurons and cause a hypertensive response, the cheese effect.
The high selectivity of safinamide for MAO-B makes no die-
tary restrictions necessary. Reversibility explained by noncova-
lent binding to the core of the enzyme has been demonstrated
330in in vitro experiments [61]. The reversibility of safinamide
avoids potential drug interactions [56].
Studies of the pharmacokinetics and pharmacodynamics of
safinamide in healthy volunteers showed that a relevant inhi-
bition of MAO-B starts at a dose of 25 µg/kg and is dose-
335dependent and progressive, with full inhibition observed at a
single dose > 600 µg/kg. No inhibition of MAO-A was
observed. The inhibition of MAO-B was effective in a dose-
related manner in the microgram per kilogram range and
complete in the milligram/kilogram range. Safinamide inhib-
340its the inactivation of both exogenous dopamine formed from
LD and endogenous dopamine [50].
In clinical studies, elevation of the dose of safinamide
administered above the dose providing complete MAO-B
inhibition provides a further clinical improvement, suggesting
345that, besides MAO-B inhibition, safinamide also exhibits
other modes of action. The non-dopaminergic mode of action
occurs through the inhibition of glutamate release by blocking
the activity of the voltage-dependent sodium channels [47,62,63].
Safinamide displays high affinity for sodium channel binding
350site II. Inhibition of the fast sodium channel is concentration-
and state-dependent. Safinamide is more potent at depolar-
ized membrane potentials, when most of the channels are
inactivated, as compared with the resting potential, suggesting
Table 2. The place of safinamide in the treatment approaches of Parkinson’s disease.
Dopaminergic therapy Non-dopaminergic therapy
Levodopa
LCIG therapy
Dopamine agonists
Pramipexole
Ropinirole
Apomorphine pump
MAO-B inhibitors
Rasagiline
Selegiline
Safinamide
Anticholinergics
Benztropine
Trihexyphenidyl
Ethopromazine
Antiglutamatergic agents
Amantadine
Surgical approaches
DBS
Ablative surgery
Neural transplantation and gene therapy
Drugs tested for symptomatic, antidyskinetic and neuroprotective properties
Adenosine A2A receptor antagonistsAQ8 Istradefylline
Glutamate antagonists Amantadine, kynurenines, safinamide
Glutamate receptor-related compounds MGluR5 antagonists, MGluR4 agonists
Antiepileptic drugs with complex mechanism of action Safinamide, zonisamide, levetiracetam
Vitamins Folic acid, vitamin D
Antioxidants, scavenger of free radicals, compounds acting on mitochondria Coenzyme Q10, creatine, inosine, vitamin E
Catecholamine reuptake inhibitor
a2-adrenergic receptor antagonists
Nicotine receptor agonist
Serotonin modulators
L-type Ca++ channel blocker
DBS: Deep brain stimulation; LCIG: Levodopa-carbidopa intraintestinal gel; MAO: Monoamine oxidase.
Safinamide
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that safinamide preferentially interacts with the inactivated
355 sodium channel. Safinamide keeps the sodium channels in
an inactivated state and prevents their activation. The block-
ade is enhanced during high-frequency stimulation, when
the channels are in an inactivated state. This suggests that
safinamide leaves the physiological activity unaffected and
360 depresses abnormal activity [47].
In rat cortical neurons, safinamide modulates N-type
calcium channels and might therefore inhibit presynaptic neu-
rotransmitter release. Safinamide inhibits glutamate release in
animal models [47]. At high doses, safinamide inhibits dopa-
365 mine uptake [52,64] and might also inhibit dopamine reuptake
and enhance dopamine release [65]. Diminution of glutamate
release may have a neuroprotective property [62].
The neuroprotective effect has been studied both in cell
cultures and in animal models [58]. Safinamide prevents
370 in vitro veratridine-induced neuronal cell death and protects
the hippocampal neurons in rat from kainic acid-induced
neuronal loss [47]. In MPTP-lesioned mice, pretreatment
with safinamide prevented the forebrain dopamine depletion
and neuronal death in the SN, an effect also exhibited by sele-
375 giline and rasagiline [66]. Treatment with safinamide after
MPTP administration to black C57 mice led to a dose-
dependent sparing of the dopaminergic neurons relative to
the control [47]. In another experiment, safinamide adminis-
tered 30 min prior to and after bilateral carotid artery occlu-
380sion in Mongolian gerbils resulted in complete prevention
of the hippocampal neuronal damage [58].
The antidyskinetic effect of safinamide has been tested in
MPTP-lesioned dyskinetic macaque monkey, in comparison
with and in combination with amantadine. LID and Parkin-
385sonian symptoms were measured and plasma levels of safina-
mide were monitored during the experiments. Two acute
and one semi-chronic experiment were conducted. Safina-
mide pretreatment dose-dependently reduced the duration
and the intensity of dyskinesia measured by the LID scores.
390An inverse correlation was found between the LID and the
safinamide blood levels. Safinamide also prolonged the dura-
tion of the effect of LD as compared with amantadine, which,
although reducing LID, also reduced the duration of the
antiparkinsonian response to LD. When amantadine was
395added to safinamide, only a modest additional antidyskinetic
effect was achieved and no reduction in the duration of the
antiparkinsonian effect of LD was seen [67].
Protein
aggregation
Mitochondrial
dysfunction
Excitotoxicity
Loss of neurons
in the SNc
Dopamine-
deficient state
Parkinson’s disease
Involvement of
other
neurotransmitter
systems
Safinamide
Safinamide 1
Oxidative
stress
Safinamide
3
4
2
Figure 1. The effect of safinamide in the pathomechanism of PD is shown. Protein aggregation, oxidative stress,
mitochondrial dysfunction and presumably the glutamate-induced excitotoxicity are major factors contributing to the
pathology of PD. These factors cause the loss of pigmented neurons of the substantia nigra pars compacta leading to a
dopamine-deficient state. The dopamine-deficient state, combined with the involvement of other neurotransmitter systems,
is responsible for the development of the motor and non-motor symptoms of the disease. Safinamide improves the
dopamine-deficient state through MAO-B inhibition (1) and improves the motor symptoms. It also exhibits an
antiglutamatergic effect (2), which may be beneficial in the treatment of dyskinesia. Safinamide might also have a
neuroprotective role; it may possibly also lower oxidative stress through MAO-B inhibition (3) and exert an anti-excitotoxic
effect through glutamate inhibition (4).
PD: Parkinson’s disease; MAO: Monoamine oxidase.
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The tremorolytic action of safinamide has been investigated
in animal models. Safinamide significantly reduced the trem-
400 ulous jaw movements induced in rats by pilocarpine, pimo-
zide and galantamine, supporting the efficacy of safinamide
in Parkinsonian tremor [68].
7. Clinical trials with safinamide in PD
7.1 Clinical efficacy of safinamide as compared with
405 placebo
The safety and efficacy of different doses of safinamide (0.5 or
1 mg/kg) on motor function were investigated in a 3-month
placebo-controlled study (Study 009) on 172 early stage PD
patients [69]. Those patients with a > 30% improvement in
410 the UPDRS motor subscore relative to the baseline were
defined as responders. The responder rate in the group on
high-dose safinamide (median 70 mg/day) was 37.5%, which
was significantly higher than that in the placebo group
(21.4%). The decrease in UPDRS motor score was 3.3. The
415 study also proved the safety of safinamide [70].
7.2 Safinamide as adjunct therapy to a DAA
Safinamide was the first medication tested in clinical trials as
an adjunct to DAAs. In the subgroup of the patients enrolled
in the above study who were on a stable dose of a single DAA,
420 the patients receiving safinamide as an adjunct to a DAA
exhibited a significantly better response as compared with pla-
cebo. A small open-label study led to the same result [65,70].
The efficacy and safety of a high (150 -- 200 mg) and a low
(50 -- 100 mg) dose range of safinamide as add-on therapy to
425 a single stable dose of DAA were evaluated in comparison
with placebo in a study enrolling 269 patients (Study 015,
NCT00643045). The primary end point was the change in
the UPDRS motor scores relative to the baseline. The exten-
sion study (Study 017, NCT00642889) was a 12-month, ran-
430 domized, double-blind, placebo-controlled preplanned study
to evaluate the long-term efficacy and safety of safinamide as
add-on therapy for early stage PD. A total of 227 patients
were randomized to 100 or 200 mg/day safinamide or to pla-
cebo added to a DAA. The primary efficacy end point was the
435 time from baseline to an increase in the DAA dose, addition
of another DAA, addition of LD or other PD treatment
(defined as intervention) or discontinuation due to the lack
of efficacy. The treatment was well tolerated, with no differ-
ence in the occurrence of adverse events between the safina-
440 mide and the placebo groups. The median time to
intervention for the pooled safinamide groups was 559 days,
whereas in the placebo group it was 466 days, although the
difference between the two groups did not reach statistical sig-
nificance. Patients receiving 100 mg safinamide exhibited an
445 intervention rate that was significantly lower than that of the
placebo group and a delay of 9 days in the median time to
intervention, as revealed by the post-hoc analysis [71]. The
lower dose of safinamide added to the DAA resulted in a sta-
tistically significant improvement in UPDRS motor scores
450over the placebo group. A statistically significant improve-
ment was also measured in the quality of life scores in the
pooled dose group and in the individual dose groups [70].
MOTION (NCT00605683) was a 24-week, randomized,
double-blind, placebo-controlled international Phase III
455clinical trial that investigated safinamide in early idiopathic
PD as add-on therapy to a DAA. A total of 679 patients
with a disease duration of < 5 years who had been on a stable
dose of a single DAA for at least 4 weeks prior to enrolment
were randomized to receive either 50 mg of safinamide,
460100 mg of safinamide or placebo as add-on therapy. The pri-
mary end point was the change in the mean UPDRS-section
III value relative to the baseline. The secondary outcome
measures were the change from baseline to week 24 in the
ADL, cognition, the health-related quality of life, the change
465in global clinical status and the responder rates in the motor
function evaluation [72]. Safinamide was well tolerated, with
adverse events such as nausea, dizziness, somnolence, head-
ache and back pain reported. The dropout rate was about
11%, with 607 patients completing the trial. Safinamide
470100 mg/day as add-on to DAA therapy significantly improved
the UPDRS motor score and certain quality of life measures
as compared with the placebo. The extension study
(NCT01028586) enrolled 507 patients receiving 50 or
100 mg of safinamide or placebo for 78 weeks. The primary
475end point was the time to intervention, whereas the secondary
end points were the proportion of patients requiring interven-
tion, the change in UPDRS motor scores, the ADL scores,
a change in the CGI and quality of life and cognitive
measures [73].
480Rasagiline was also investigated as add-on therapy to DAAs
in early stage PD patients. ANDANTE was a Phase IV,
18-week, placebo-controlled, randomized, double-blind study
(NCT01049984) to assess the efficacy and safety of rasagiline
as add-on therapy to a single stable dose of a DAA (6 mg/day
485of ropinirole or 1 mg/day of pramipexole) in early stage PD
patients, suboptimally controlled by the DAA. The primary
outcome measure was a change in the total UPDRS score
value, whereas the secondary outcome measures were the
UPDRS subscore values and the CGI-I values. Of the
490328 patients randomized, 321 were included in the analysis
of the clinical efficacy. The results were presented at the
MDS Congress in 2013; significant improvements in the
UPDRS total score and motor subscore values were reported
as compared with the placebo arm. No significant differences
495in the occurrence of adverse events were seen in the two study
arms and only a few patients needed LD rescue therapy. The
addition of rasagiline to a DAA significantly improves the
motor function with a favorable adverse event profile [74].
7.3 Safinamide as adjunct therapy to LD
500The potential antidyskinetic properties of safinamide were
explored in clinical trials on PD patients suffering from
LID. A total of 26 patients were enrolled in a Phase II, dou-
ble-blind, placebo-controlled, parallel-group, dose-escalation
Safinamide
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trial (Safinamide-LID, NCT01113320). The primary out-
505 come measure was the maximum reduction in Unified Dyski-
nesia Rating Score compared to the baseline. Secondary end
points were the total on and off times as evaluated by the
patient diaries and the changes in the UPDRS scale and
subscale scores and in the CGI [75].
510 Study 016 (NCT01187966) and its extension study (Study
018, NCT01286935) evaluated the short- and the long-term
safety and efficacy of safinamide as add-on therapy to LD in
patients with mid-to-late stage PD. The 24-month data
were presented in 2011 at the poster session of the AAN meet-
515 ing [76]. In Study 016, 669 patients with idiopathic PD on a
stable dose of LD therapy were randomized to receive
50 mg/day of safinamide (223 patients), 100 mg/day of safi-
namide (224 patients) or placebo (222 patients) for 6 months.
The 6-month treatment with safinamide (50 or 100 mg/day)
520 significantly improved the motor function, increased the aver-
age duration of the on time with no dyskinesia or with minor
dyskinesia and decreased the average duration of the off time
relative to the placebo. Patients who completed the 24-week
trial could continue the treatment in the extension study
525 (544 patients). Changes in the LD dose and treatment with
other PD medication except a MAO-B inhibitor, were
allowed. The primary end point was the degree of improve-
ment in the Dyskinesia Rating Scale (DRS) scores during
the on time as compared with the baseline value. At 2 years,
530 the differences seen in the DRS scores for the 50 mg/day
and the 100 mg/day safinamide groups were not significant,
but the post-hoc analysis of the 100 mg/day safinamide sub-
group with severe dyskinesia (DRS scores > 4 at baseline)
demonstrated a significant improvement in the DRS scores
535 (p = 0.03). Patient diary analysis showed that the improve-
ment reported at 6 months was still present after 2 years of
therapy. An increase in the daily on time with no/minor dys-
kinesia and a decrease in the daily off time were reported.
Overall, the improvement was greater in the 100 mg/day safi-
540 namide group for the motor scores, ADL scores and clinical
status. These patients were more likely to achieve a reduced
LD dose than the patients from the other groups. There
were few dropouts and no safety concerns emerged [76-79].
The SETTLE trial (NCT00627640) evaluated the efficacy
545 and safety of two different doses of safinamide
(50 -- 100 mg) as compared with placebo as add-on therapy
to a stable dose of LD and other anti-Parkinson drugs
(DAAs, anticholinergics, amantadine and/or COMT inhibi-
tors) over 24 weeks in 549 subjects with advanced PD.
550 The principal end point was the increase in mean on time
without troublesome dyskinesia, as recorded in the patient
diaries. A significant benefit of both doses of safinamide
over placebo was revealed, with a significant improvement
of > 1 h in the on time as reported by the patient diaries
555 and the caregiver and a 30% or more improvement in the
motor symptoms (p = 0.018). Benefits were observed in
the off time, in the quality of life measures (39-Item Parkin-
son’s Disease Questionnaire [PDQ-39] andAQ6 EQ-5D), in the
CGI of severity and change and also in the off time after
560the morning dose of LD. The onset of the effect was rapid:
improvements in both the on time and the off time were
observed from week 2 onward. Tolerability was good and
484 patients completed the trial. No relevant changes were
detected in vital signs, laboratory results, ECG or ophthal-
565mological examinations. Adverse events such as nausea,
urinary tract infections, falls, back pain and dyskinesia were
reported. Transient mild dyskinesia occurred more fre-
quently with safinamide but did not lead to discontinuation
of the study. No increase in troublesome dyskinesia was
570observed [80,81].
An open-label trial (NCT00865579) is currently evaluating
the long-term safety and tolerability of safinamide in PD
patients who have already completed a previous study with
safinamide. The physical and neurological condition together
575with other safety parameters, such as vital signs, laboratory
evaluations, ECG and quality of life measures were compared
at different visits with the baseline [82].
7.4 Safinamide for PD-associated cognitive
impairment
580In order to explore the potential benefit of safinamide on
cognitive impairment associated with PD 103, cognitively
impaired, but non-demented PD patients were enrolled in a
double-blind, randomized, placebo-controlled, parallel group
Phase II clinical trial (NCT01211587). The primary outcome
585measures were the PD Cognitive Rating Scale and subscale
scores, DRS-2 and subscale scores, the CGI change in cogni-
tive dysfunction, the Grid-Hamilton Depression Rating scale,
the PD sleep scale and the apathy scale scores [83].
8. Safety and tolerability issues
590In the clinical studies detailed above, the tolerability proved to
be good. The clinical trials were accompanied by a dropout
rate of only about 11%. No relevant changes in vital signs,
laboratory results, ECG or other examinations occurred.
Adverse events such as nausea, dizziness, falls, somnolence,
595headache, back pain, urinary tract infections and transient
mild dyskinesia were reported [73,80,81].
9. Regulatory affairs
The results of the SETTLE and MOTION trials were
presented at the AAN, MDPD and MDS conferences. The
600Newron Company has started meetings with the European
health authorities to discuss the results of the preclinical and
clinical trials in order to achieve support for the registration
of safinamide as an add-on therapy to DAAs in early stage
PD and to LD in advanced stage PD. Additional discussions
605with European health authorities, EMA and FDA for
European and US approval and the regulatory submission
were planned for QIV/2013 [84].
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10. Conclusion
The a-aminoamide derivative safinamide exhibits both a
610 dopaminergic and a non-dopaminergic mode of action. It is
a potent selective and reversible MAO-B inhibitor, a
sodium-channel antagonist and an inhibitor of glutamate
release. Safinamide has a dose-dependent, dose-proportional
and linear favorable pharmacokinetic profile. Its biotransfor-
615 mation is extensive. It does not interact with CYP. Safinamide
is well tolerated, with few side effects.
Safinamide was investigated in Phase III clinical trials as
adjunct therapy to DAAs for patients with early stage PD
and to LD therapy for patients in the mid-to-late stages of
620 PD. The results from the MOTION and SETTLE studies
confirmed that safinamide comprises effective add-on therapy
to DAAs in early stage PD patients and to LD in mid-to-late
stage PD. Safinamide significantly improved the motor func-
tion, as assessed by the UPDRS motor score in the MOTION
625 study and improved the motor fluctuation assessed by the on
time without troublesome dyskinesia in mid-to-late stage PD
patients in the SETTLE study. In the Phase III trials, signifi-
cant improvements in the quality of life, assessed by the
PDQ-39 test and/or by the EQ-5D scale were seen. Box 1
630 presents the main characteristics of safinamide.
11. Expert opinion
The cause of PD is multifactorial and the pathomechanism of
the disease is not completely understood. There are many
unmet needs of PD patients, such as the suitable treatment
635 of many of the non-motor symptoms and a neuroprotective
therapy capable of protecting the dopaminergic neurons
from premature death. LD is still the best symptomatic treat-
ment available, capable of alleviating the motor symptoms of
the disease. The MAO-B inhibitors provide a lower symp-
640 tomatic effect on motor symptoms as compared with LD.
Besides an effect on motor symptoms, the delayed-start stud-
ies suggest disease-modifying properties of the MAO-B inhib-
itors. As compared with the other compounds in this class of
medication, safinamide bears a more favorable pharmacoki-
645 netic profile and complex pharmacodynamic properties.
Safinamide is a unique compound exhibiting a combined
non-dopaminergic and dopaminergic mode of action. It is a
reversible MAO-B inhibitor, with a higher selectivity for
MAO-B than for MAO-A, this selectivity being greater than
650 in the cases of the other compounds available in this class of
medications. It also inhibits the voltage-sensitive sodium
channels and modulates the N-type calcium channels.
The symptomatic effect of safinamide has not yet been
compared with those of other MAO-B inhibitors. The
655 MOTION study that investigated safinamide as an add-on
therapy to DAAs in early stage PD patients revealed positive
outcomes in the post-hoc analysis for those patients taking
100 mg of safinamide. Rasagiline as add-on therapy to
DAAs (ropinirole or pramipexole) showed more pronounced
660outcomes in the ANDANTE study. However, the results
cannot be compared, due to the different inclusion criteria.
The results suggest that the combination of a DAA with a
MAO-B inhibitor delays the need for LD. Besides the symp-
tomatic effect on the motor function, already confirmed in
665clinical trials, a tremorolytic, an antidyskinetic and presum-
ably a neuroprotective effect could be further explored.
Further trials are needed to assess the effects of safinamide
on LD-induced fluctuations and dyskinesias as compared
with placebo, amantadine and COMT inhibitors. In view of
670the various mechanisms involved in PD pathology, a com-
pound combining favorable effects on dopaminergic and
non-dopaminergic, glutamatergic neurotransmission might
well have manifold effects in the treatment of PD.
The important roles played by glutamate in neurotoxicity
675and by glutamate antagonists in neuroprotection have
been demonstrated in several animal models of PD and of
other neurodegenerative disorders. Neuroactive kynurenines
with an antiglutamatergic effect are also investigated in this
respect [85-90]. Safinamide-induced neuroprotection has been
680investigated in animal models (MPTP-treated mice, a rat
kainic acid model and a gerbil ischemia model) and neuropro-
tective and neurorescuing effects have been revealed.
Further research is necessary to investigate the potential
neuroprotective effect of safinamide in PD patients.
685The place of safinamide in the therapy of PD is yet to be
determined. The favorable pharmacokinetic and side-effect
profile and the possibility that the LD dose can be reduced
when safinamide is added together with the presumed neuro-
protective properties outlined above suggest that safinamide is
690a valuable compound in the treatment of PD. It may serve as
the first line of add-on therapy to DAA and LD in the early
and the mid-to-late stage disease, respectively.
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Introduction: 
 Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of 
dopaminergic neurons in the substantia nigra pars compacta. Non-dopaminergic 
neurotransmitter systems are also involved in its pathomechanism. The aim of the treatment is 
to improve the dopamine-deficient state and to alleviate the motor and the non-motor 
symptoms. Safinamide is an αalfa-aminoamide derivative with a combined, dopaminergic and 
non-dopaminergic mode of action. Phase III clinical trials with safinamide, as add-on therapy 
to a dopamine agonist (DAA) and to levodopa (LD) in early and advanced- stage PD, 
respectively, demonstrated an improvement of the motor symptoms. 
Areas covered: 
 The review discusses the pharmacokinetic and pharmacodynamic properties of safinamide 
and provides an overview of the clinical trials conducted with safinamide in PD. A literature 
search was made in PubMed for safinamide, safinamide pharmacokinetics, PD treatment and 
monoamine oxidaseMAO-B inhibitors, and in PubMed and on the ClinicalTrials.gov site for 
clinical trials with safinamide in PD. 
Expert opinion: 
 The place of safinamide in the therapy of PD is yet to be determined. However, the authors 
believe that safinamide is a valuable drug in the treatment of PD treatment with favorable 
pharmacokinetic and side-effect profiles. Data suggests so far suggest that it can be used 
beneficially as add-on therapy both to DAAsdopamine agonists in early PD and to 
LDlevodopa in the later stages of the disease. 
Keywords: dopaminergic, monoamine oxidase-B inhibitors, non-dopaminergic, Parkinson’s 
disease, safinamide 
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ADAGIO  a randomized, double-blind, placebo-controlled, delayed-start study to 
assess rasagiline as a disease modifying therapy in Parkinson’s disease 
ADL   activities of daily living 
ANDANTE  Rasagiline as add on to dopamine agonists in the treatment of 
Parkinson's Disease trial 
BBB   blood-–brain barrier 
CGI   clinical global impression 
COMT  catechol-O- methyl transferase 
CYP450  cytochrome P450 
DA   dopamine agonists 
DRS   Dyskinesia Rating Scale 
EQ-5D  European Quality of life scale (EuroQoL) 
LARGO  Lasting effect in Adjunct therapy with Rasagiline Given Once daily 
LCIG   levodopa-carbidopa intra-intestinal gel  
LD   levodopa 
LID   levodopa- induced dyskinesia 
MAOB  monoamine oxyidase B 
MOTION  SafinaMide add-On To dopamine agonist for early Idiopathic 
ParkinsON’s disease with motor fluctuations 
MPTP   1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
PD   Parkinson’s disease  
PDQ-39  39-Item Parkinson’s Disease Questionnaire 
PRESTO  Parkinson's Rasagiline: Efficacy and Safety in the Treatment of "OFF" 
REM   rapid eye movement 
RLS   restless legs syndrome 
ROS   reactive oxygen species 
SETTLE  SafinamidE Treatment as add-on To LEvodopa in idiopathic 
Parkinson’s disease with motor fluctuations 
SN   substantia nigra 
TEMPO  TVP-1012 (an early name for rasagiline) in Early Monotherapy for 
Parkinson's Disease Outpatients 
UDysRS  Unified Dyskinesia Rating Scale 
UPDRS  unified Parkinson’s disease rating scale 
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1. Introduction 
Parkinson’s disease (PD) is a neurodegenerative disorder with a frequency that increases with 
age. The cause of the neurodegenerative process in PD is not known; several mechanisms are 
involved in its development, including oxidative stress, inflammatory changes, proteosomal 
dysfunction and mitochondrial dysfunction 1,2,3. The pathogenetic changes include the loss 
of dopaminergic neurons in the substantia nigra (SN) pars compacta and the appearance of 
Lewy bodies within the pigmented neurons of the SNsubstantia nigra. It is presumed that 
motor symptoms occur at a loss of about 60- – 80% of the dopaminergic neurons of in the 
SNsubstantia nigra. Non-dopaminergic neurotransmitter systems, such as the serotonergic, the 
cholinergic, the adrenergic and glutamatergic, are also involved in the pathomechanism of the 
disease 4. Besides the motor symptoms related to the dopamine-deficient state, non-motor 
symptoms can occur, even in the early stages of the disease, and impair the quality of life of 
the patients 5. PD symptoms are summarized in Table 1. 
2. Treatment approaches in PD 
The treatments available at present mainly improve the motor symptoms caused by the 
dopaminergic loss. This can be achieved by supplying the dopamine precursor levodopa (LD) 
to increase the synthesis of dopamine, by stimulating the dopamine receptors or by acting on 
the metabolism of dopamine. As a result of the improving understanding[AuQ1] of the complex 
pathomechanism of the disease, treatment has focused recently focused on non-dopaminergic 
medication investigated for the treatment of the motor and non-motor symptoms and for 
alleviation of the dyskinesia. Effective neuroprotective therapy, that is capable of halting the 
disease progression, is not available 1,6,7. 
The gold standard of the symptomatic treatment of the disease is LDlevodopa therapy. 
LDevodopa, a dopamine precursor capable of crossing the blood-–brain barrier, is taken up by 
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the dopaminergic neurons and is decarboxylated to dopamine presynaptically in the basal 
ganglia. The peripheral metabolism responsible for the side- effects is reduced by a peripheral 
decarboxylase inhibitor. In the first few months or years of LDlevodopa therapy, a stable 
improvement of the motor symptoms can be seen. In time, however, the effect of LDlevodopa 
wears off a few hours after LDlevodopa intake. Later, on and off motor fluctuations occur, 
related to the fluctuations of the peripheral LDlevodopa concentration, but not correlated to 
the medication intake in the late stages of the disease. The progressive decrease in the number 
of dopaminergic neurons in the SNsubstantia nigra results in an inability of the striatum to 
buffer the variability in the brain dopamine concentrations caused by a short-acting 
dopaminergic agent. Oral substitution therapy is considered to cause a pulsatile stimulation of 
the dopamine receptors, which in turn is considered to underlie the development of motor 
fluctuations and levodopaLD-induced dyskinesia (LID). A continuous stimulation of the 
dopaminergic receptors presumably causes less fluctuation and dyskinesia 8,9. The dopamine 
agonists (DAAs) have longer half-lives than that of LDlevodopa, but provide less 
symptomatic effect. The cathechol-O-methyl transferase (COMT) inhibitors and the 
monoamine- oxidase (MAO) inhibitors are dopaminergic agents which inhibit the dopamine 
metabolizing enzymes. The COMT inhibitors increase the bioavailability and the half-life of 
LDlevodopa and reduce the fluctuations of plasma LDlevodopa. COMT inhibitors are 
recommended for patients who exhibit the wearing-off phenomenon 5, as they improve and 
may also prevent the onset of wearing-off. In the STRIDE-PD study, the addition of the 
COMT inhibitor entacapone to LDlevodopa resulted in earlier and more dyskinesia as 
compared with levodopaLD/carbidopa alone 10. 
AltThough LDlevodopa has a short half-life, in the early stages of disease, the presynaptic 
terminals are capable of storing dopamine and releasing it in a physiological manner. In 
advanced disease stages, the dopamine release becomes synchronous with the peripheral 
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LDlevodopa bioavailability and plasma levels and leads to a pulsatile stimulation presumably 
underlying motor complications. The levodopaLD/carbidopa intraintestinal gel (LCIG) 
therapy by-passes the gastric emptying, provides a continuous LDlevodopa delivery and a 
smoother plasma LDlevodopa level with less fluctuations 11,12,13. The coefficient of 
variation for the plasma concentration of LDlevodopa is decreased by LCIG therapy as 
compared with oral therapy 11. Dyskinesias are presumably diminished as a result of an 
effect on the central therapeutic window and not by a reduction of the LDlevodopa 
concentration, since the daily total dose is not reduced as compared with the previous oral 
dose 14. Clinical trials have shown the efficacy of LCIG therapy in reducing dyskinesias, 
motor fluctuations 15 and off-time 16,17,18,19,20,21. Improvements were revealed in gait 
disorder 22,23 and some of the non-motor features of PD, such as sleep, fatigue, attention, 
memory and cardiovascular, gastrointestinal and urinary functions 17,22,23. Non-motor 
symptoms, such as neuropsychiatric symptoms, sleep disturbances, autonomic symptoms and 
sensory symptoms, can occur at any stage of the disease and affect the quality of life. The role 
of dopaminergic pathology in the development of the non-motor symptoms has been revealed 
24. Some of the non-motor symptoms, such as depression, anhedonia, panic attacks related to 
off periods, restless legs syndrome, urinary urgency, nocturia, erectile impotence, 
constipation, fatigue and pain related to PD, are improved by the dopaminergic therapy, 
although most of the non-motor symptoms are unresponsive, exacerbated or induced by PD 
therapy 25. The pulsatile dopaminergic stimulation is presumed to be responsible for the 
development of non-motor fluctuations, and a continuous dopaminergic stimulation might 
improve non-motor fluctuations 26. 
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Other drugs used in the treatment of PD are amantadine, which is valuable in the treatment of 
LID, and anticholinergics, which are beneficial in the treatment of PD-related tremor, but 
whose use is limited by their side- effects 7. 
3. MAO-B inhibitors 
MAO-B is a key enzyme in the metabolism of dopamine in the brain. MAO-B inhibitors can 
be used as monotherapy in the earlier stages of the disease or as add-on therapy to 
LDlevodopa in the more advanced stages. There is evidence of the role of a mitochondrial 
dysfunction and oxidative stress in the pathomechanism of genetic and sporadic forms of PD. 
A deficiency of complex I of the mitochondrial electron transport chain has been revealed in 
PD. The mitochondrial dysfunction is accompanied by the oxidative stress caused by reactive 
metabolites of dopamine and alterations in the levels of glutathione and iron in the 
SNsubstantia nigra 27. The action of MAO-B is central to the processes involved in oxidative 
stress and oxidative damage in PD. MAO-B activates 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) to MPP+, enzymatically converts dopamine to hydrogen peroxide 
and activates other potential toxins, such as isoquinolines and βbeta-carbolines. In animal 
models, MAO-B inhibitors prevent the formation of free radicals, and prevent the oxidation of 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to MPP+ and therebyfore its 
neurotoxic effect, but no disease-modifying effect has been demonstrated for these 
compounds to date 28,29. MAO-B inhibitors may protect against the generation of free 
radicals formed from the oxidation of dopamine. Selegiline may increase neurotrophic 
factor[AuQ2] activity and may upregulate molecules which protect against oxidative stress and 
exerts an anti-apoptotic role, such as glutathione, superoxide dismutaseSOD, catalase, and B-
cell lymphomaCL-2 protein 30,31,32. 
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The selective irreversible MAO-B inhibitors selegiline and rasagiline reduce LDlevodopa 
breakdown. A recent study evaluated the effect of long-term MAO-B inhibitor treatment with 
selegiline or rasagiline on MAO-A activity. Plasma samples were taken from PD patients on 
MAO-B inhibitor therapy, from PD patients without MAO-B inhibitor treatment and from 
healthy controls. A 70% reduction in MAO-A activity was detected ex vivo in PD patients on 
MAO-B inhibitor therapy as compared with the other two groups. No difference was detected 
between PD patients taking selegiline and rasagiline. The effect of selegiline on MAO-A 
activity in vitro was also evaluated by incubating human control standardized plasma samples 
with selegiline; the IC50 of selegiline was determined as 44 µM for MAO-A. The results were 
partially explained by pharmacokinetic considerations. About 4 h after the last medication 
intake, the plasma concentrations of selegiline and rasagiline were high enough to inhibit 
MAO-A activity. Long-term treatment with selegiline has previously been revealed to 
increase its Tt1/2 and keep the concentration in a range high enough to inhibit MAO-A. The 
loss of specificity for MAO-B at higher concentrations and the inhibition of both isoenzymes 
may affect both the peripheral and the brain MAO. This results in a reduced breakdown of the 
neurotransmitter amines and might also reduce the synthesis of reactive oxygen speciesROS 
and other toxic compounds, but the role of the MAO-B/MAO-A interaction in the 
pathomechanism of PD and the possible neuroprotective effect of MAO-B inhibitors 
neccessitate further investigations 33. 
A large, multicenter, randomized, double-blind, placebo-controlled trial (DATATOP) proved 
that selegiline delayed the need for LDlevodopa therapy in early PD 34, suggesting a 
neuroprotective effect. The post- hoc analysis revealed the symptomatic effects of selegiline 
responsible for some of the beneficial effects and the long-term follow- up of the patients 
showed that selegiline does not stop the disease progression 1. The delayed start studies 
TEMPO and ADAGIO (a randomized, double-blind, placebo-controlled, delayed-start study 
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to assess rasagiline as a disease modifying therapy in Parkinson’s disease) showed that an 
early initiation of rasagiline therapy for early- stage PD patients had a beneficial effect on the 
motor symptoms, which was preserved during the long-term follow- up. In the ADAGIO 
study, patients were randomized to 1 or 2 mg/day of rasagiline or placebo for 9 months. In the 
second part of the study, all patients were treated with active medication for another 9 months. 
Patients originally randomized to rasagiline 1 mg/day demonstrated less progression of the 
clinical disability than those randomized to rasagiline after a delay of 9 months. The benefit 
was significant for the 1 mg/day dose, but not for the 2 m/day dose 35,36,37. 
In the LARGO and PRESTO trials for advanced-stage disease, the patients who received 
rasagiline exhibited a reduction of the off time, and significant improvements in the activities 
of daily living (ADL), and the motor subscores of the Unified Parkinson’s dDisease rRating 
sScale (UPDRS) and in the clinical global impression (CGI) scale score. A reduction of the 
daily dose of LDlevodopa could also be achieved 38,39,40. In a trial on early PD patients, 
rasagiline monotherapy provided benefits in the treatment of some of the non-motor 
symptoms 41. A meta-analysis of the Medline and the Cochrane Library database showed 
that rasagiline as monotherapy reduces the motor scores in early PD, whereasile as add-on 
therapy to LDlevodopa, it reduces the off time in the more advanced stages of the disease 42. 
4. Safinamide 
Safinamide ((S)-(+)-2-[4-(fluorobenzyl) oxybenzyl]aminopropan amide methanesulfonate) is 
a water-soluble enantiomeric αalfa-aminoamide derivative with a combined dopaminergic and 
non-dopaminergic mode of action (Box 1, for the chemical structure). It has been developed 
as antiepileptic medication. Milacemide was first shown to exhibit weak anticonvulsant 
activity and inhibition of MAO-A and -B 43,44,45. New αalfa-amino-amides have been 
developed, among which safinamide has been further investigated. Safinamide displays 
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MAO-B inhibitory activity and a voltage-sensitive channel-blocking activity; its 
neuroprotective and neurorescuing properties have also been investigated. It can be used as 
add-on treatment to LDlevodopa or a DAA and can improve motor symptoms 46,47 and 
some of the non-motor symptoms of PD 48. Safinamide has completed the Phase III 
development program as add-on therapy to DAAs and to LDlevodopa in patients with early 
and mid- to- late -stage PD, respectively, and its beneficial effect on the motor symptoms of 
PD has been confirmed 49. Table 2 highlights the place of safinamide in the therapeutic 
spectrum of PD and Table 3 presents some of the clinical trials conducted with safinamide in 
PD patients. 
5. Pharmacokinetics of safinamide 
Orally administered safinamide displays favorable pharmacokinetic properties, which are 
linearly and proportionally related to the administered dose 50. The absorption is complete 
and reliable and is not appreciably influenced by food. The absolute bioavailability is high, at 
95%. The pharmacokinetics is dose-proportional across the therapeutic dose range, with low 
inter-subject variability. In a study of the pharmakcokinetics of safinamide, administered as a 
single dose of 400 mg [14C] safinamide methanesulfonate to healthy volunteers, maximum 
concentration was achieved at 1 h for the parent drug, at 7 h for the plasma and at 1.5 h for the 
whole-blood [14C] radioactivity 51. Its extravascular distribution is extensive, corresponding 
to the high lipophilicity. The plasma protein binding (92%) is apparently lower than the 
extravascular tissue binding 50,52. Safinamide reaches high concentrations in the CNS 47. 
The biotransformation of safinamide is considerable. About 1.5% and 7% is excreted in 
unchanged form in the feces and urine, respectively 52, which is indicative of the practically 
complete absorption of the drug and very little biliary excretion. The metabolism of 
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safinamide has two principal routes. One metabolic route leads to a carboxylic acid metabolite 
(NW-1689) and presumably involves several enzymes, such as CYPcytochrome P450 
enzymes, MAO-A and the aldehyde dehydrogenases. A CYP3A4 inhibitor (troleandromycin) 
exerted only a minimal effect on the clearance of safinamide in vitro. An investigation of the 
effects of another CYP3A4 inhibitor, ketoconazole, on the metabolic clearance of safinamide 
in healthy individuals in a monocentric, open-label, randomized, two-period cross-over 
clinical trial showed that the CYP3A4-mediated metabolism did not contribute significantly 
contribute to the metabolic clearance of safinamide in vivo 53. The results also revealed that 
safinamide can be co-administered with potent CYP3A4 inhibitors without a requirement for 
dose adjustment. The other metabolic route is the direct amide hydrolysis of safinamide by 
amidases, leading to the metabolite safinamide acid (NW-1153). In vivo animal studies on 
rats, and in vitro studies on rat and human hepatocytes, suggested that NW-1153 is not a 
metabolic end- product, but an intermediate, converted to NW-1689. 
The main circulating plasma metabolite[AuQ3] of safinamide is NW-1689, which undergoes 
glucuronidation to become NW-1689 acyl glucuronide. The deaminated acid and the N-
dealkylated acid have been identified as major metabolites in the plasma and urine. Other 
urinary metabolites identified in a more recent study are the betaβ-glucuronide of the N-
dealkylated acid, monohydroxy safinamide and minor urinary metabolites such as the glycine 
conjugate of the N-dealkylated acid and 2-(4-hydroxybenzylamino)propanamide 51. 
The systemic clearance of safinamide[AuQ4] is low and its. The terminal half-life is about 26 h 
54. In the case of the administration of radioactively labeled safinamide, the terminal half-life 
was 22 h for the unchanged drug and 80 h for the radioactivity. This permits a once- daily 
administration. A steady-state concentration is achieved on day 5 of the once -daily dosing 
treatment regimen 51. 
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Safinamide has proved to be safe and well tolerated. The vital signs and the biochemical 
analysis of the blood and urine showed no differences as compared with placebo. No 
difference in the pressor response to intravenous administration of safinamide was 
encountered in healthy volunteers relative to placebo administration 55,56. 
6. Pharmacodynamics of safinamide 
The precise mechanism through which safinamide improves the symptoms of PD is uncertain 
(Figure 1, for the effect of safinamide in PD). As mentioned earlier, safinamide has a 
combined dopaminergic and non-dopaminergic mechanism of action, including the selective 
and reversible inhibition of MAO-B, activity-dependent sodium channel antagonism and 
inhibition of glutamate release in vitro. The dopaminergic mode of action is through potent 
and highly selective reversible MAO-B inhibition, thereby enhancing the brain dopamine 
concentration 47,57. 
The selectivity of safinamide for MAO-B has been shown to be 1000 times higher as 
compared with placebo. The selectivity for of MAO-B over MAO-A is greater than in the 
cases of selegiline and rasagiline 47,50,52,58,59,60. In the event of unspecific MAO 
inhibition, dietary amines enter the circulation, induce noradrenaline release from peripheral 
adrenergic neurons and cause a hypertensive response, the cheese effect. The high selectivity 
of safinamide for MAO-B makes no dietary restrictions necessary. Reversibility explained by 
non-covalent binding to the core of the enzyme has been demonstrated in in vitro experiments 
61. The reversibility of safinamide avoids potential drug interactions 56. 
Studies of the pharmacokinetics and pharmacodynamics of safinamide in healthy volunteers 
showed that a relevant inhibition of MAO-B starts at a dose of 25 µg/kg and is dose-
dependent and progressive, with full inhibition observed at a single dose higher than> 600 
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µg/kg. No inhibition of MAO-A was observed. The inhibition of MAO-B was effective in a 
dose-related manner in the microgram per kilogramµg/kg range and complete in the 
milligram/kilogram range. Safinamide inhibits the inactivation of both exogenous dopamine 
formed from LDlevodopa and endogenous dopamine 50. 
In clinical studies, elevation of the dose of safinamide administered above the dose providing 
complete MAO-B inhibition provides a further clinical improvement, suggesting that, besides 
MAO-B inhibition, safinamide also exhibits other modes of action. The non-dopaminergic 
mode of action occurs through the inhibition of glutamate release by blocking the activity of 
the voltage-dependent sodium channels 47,62,63. Safinamide displays high affinity for 
sodium channel binding site II. Inhibition of the fast sodium channel is concentration- and 
state-dependent. Safinamide is more potent at depolarized membrane potentials, when most of 
the channels are inactivated, as compared with the resting potential, suggesting that 
safinamide preferentially interacts with the inactivated sodium channel. Safinamide keeps the 
sodium channels in an inactivated state and prevents their activation. The blockade is 
enhanced during high-frequency stimulation, when the channels are in an inactivated state. 
This suggests that safinamide leaves the physiological activity unaffected and depresses 
abnormal activity 47. 
In rat cortical neurons, safinamide modulates N-type calcium channels and might therefore 
inhibit presynaptic neurotransmitter release. Safinamide inhibits glutamate release in animal 
models 47. At high doses, safinamide inhibits dopamine uptake 52,64 and might also inhibit 
dopamine reuptake and enhance dopamine release 65. Diminution of glutamate release may 
have a neuroprotective property 62. 
The neuroprotective effect has been studied both in cell cultures and in animal models 58. 
Safinamide prevents in vitro veratridine-induced neuronal cell death and protects the 
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hippocampal neurons in rat from kainic acid-induced neuronal loss 47. In MPTP-lesioned 
mice, pretreatment with safinamide prevented the forebrain dopamine depletion and neuronal 
death in the SNsubstantia nigra, an effect also exhibited by selegiline and rasagiline 66. 
Treatment with safinamide after MPTP administration to black C57 mice led to a dose-
dependent sparing of the dopaminergic neurons relative to the control 47. In another 
experiment, safinamide administered 30 min prior to and after bilateral carotid artery 
occlusion in Mongolian gerbils resulted in complete prevention of the hippocampal neuronal 
damage 58. 
The antidyskinetic effect of safinamide has been tested in MPTP-lesioned dyskinetic macaque 
monkey, in comparison with and in combination with amantadine. LID and pParkinsonian 
symptoms were measured and plasma levels of safinamide were monitored during the 
experiments. Two acute and one semi-chronic experiment were conducted. Safinamide 
pretreatment dose-dependently reduced the duration and the intensity of dyskinesia measured 
by the LID scores. An inverse correlation was found between the LID and the safinamide 
blood levels. Safinamide also prolonged the duration of the effect of LDlevodopa as 
compared with amantadine, which, although reducing LID, also reduced the duration of the 
antiparkinsonian response to LDlevodopa. When amantadine was added to safinamide, only a 
modest additional antidyskinetic effect was achieved and no reduction in the duration of the 
antiparkinsonian effect of LDlevodopa was seen 67. 
The tremorolytic action of safinamide has been investigated in animal models. Safinamide 
significantly reduced the tremulous jaw movements induced in rats by pilocarpine, pimozide 
and galantamine, supporting the efficacy of safinamide in pParkinsonian tremor 68. 
7. Clinical trials with safinamide in PD 
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7.1 Clinical efficacy of safinamide as compared with placebo 
The safety and efficacy of different doses of safinamide (0.5 or 1 mg/kg) on motor function 
were investigated in a 3-month placebo-controlled study (Study 009) on 172 early stage PD 
patients 69. Those patients with a >more than 30% improvement in the UPDRS motor 
subscore relative to the baseline were defined as responders. The responder rate in the group 
on high-dose safinamide (median 70 mg/day) was 37.5%, which was significantly higher than 
that in the placebo group (21.4%). The decrease in UPDRS motor score was 3.3. The study 
also proved the safety of safinamide 70. 
7.2 Safinamide as adjunct therapy to a DAA 
Safinamide was the first medication tested in clinical trials as an adjunct to DAAs. In the 
subgroup of the patients enrolled in the above study who were on a stable dose of a single 
DAA, the patients receiving safinamide as an adjunct to a DAA exhibited a significantly 
better response as compared with placebo. A small open-label study led to the same result 
65,70. 
The efficacy and safety of a high (150 –to 200 mg) and a low (50 –to 100 mg) dose range of 
safinamide as add-on therapy to a single stable dose of DAA were evaluated in comparison 
with placebo in a study enrolling 269 patients (Study 015, NCT00643045). The primary end- 
point was the change in the UPDRS motor scores relative to the baseline. The extension study 
(Study 017, NCT00642889) was a 12-month, randomized, double-blind, placebo-controlled 
pre-planned study to evaluate the long-term efficacy and safety of safinamide as add-on 
therapy in for early stage PD. A total of 227 patients were randomized to 100 mg or 200 
mg/day safinamide once daily, or to placebo added to a DAA. The primary efficacy end- point 
was the time from baseline to an increase in the DAA dose, addition of another DAA, 
addition of LDlevodopa or other PD treatment (defined as intervention) or discontinuation 
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due to the lack of efficacy. The treatment was well tolerated, with no difference in the 
occurrence of adverse events between the safinamide and the placebo groups. The median 
time to intervention for the pooled safinamide groups was 559 days, whereas in the placebo 
group it was 466 days, although the difference between the two groups did not reach 
statistical significance. Patients receiving 100 mg safinamide exhibited an intervention rate 
that was significantly lower than that for of the placebo group, and a delay of 9 days in the 
median time to intervention, as revealed by the post- hoc analysis 71. The lower dose of 
safinamide added to the DAA resulted in a statistically significant improvement in UPDRS 
motor scores over the placebo group. A statistically significant improvement was also 
measured in the quality of life scores in the pooled dose group and in the individual dose 
groups 70. 
MOTION (NCT00605683) was a 24-week, randomized, double-blind, placebo-controlled 
international Phase III clinical trial that investigated safinamide in early idiopathic PD as add-
on therapy to a DAA. A total of 679 patients with a disease duration of <less than 5 years who 
had been on a stable dose of a single DAA for at least 4 weeks prior to enrolment were 
randomized to receive either 50 mg of safinamide, 100 mg of safinamide or placebo as add-on 
therapy. The primary end- point was the change in the mean UPDRS-section III value relative 
to the baseline. The secondary outcome measures were the change from baseline to week 24 
in the ADL, cognition, the health-related quality of life, the change in global clinical status 
and the responder rates in the motor function evaluation 72. Safinamide was well tolerated, 
with adverse events such as nausea, dizziness, somnolence, headache and back pain reported. 
The drop-out rate was about 11%, with 607 patients completing the trial. Safinamide 100 
mg/day as add-on to DAA therapy significantly improved the UPDRS motor score and certain 
quality of life measures as compared with the placebo. The extension study (NCT01028586) 
enrolled 507 patients receiving 50 or 100 mg of safinamide or placebo for 78 weeks. The 
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primary end- point was the time to intervention, whereasile the secondary end- points were 
the proportion of patients requiring intervention, the change in UPDRS motor scores, the 
ADL scores, a change in the CGIclinical global impression, and quality of life and cognitive 
measures 73. 
Rasagiline was also investigated as add-on therapy to DAAsdopamine agonists in early- stage 
PD patients. ANDANTE was a Phase IV, 18-week, placebo-controlled, randomized, double-
blind study (NCT01049984) to assess the efficacy and safety of rasagiline as add-on therapy 
to a single stable dose of a DAAdopamine agonist (6 mg/day of ropinirole or 1 mg/day of 
pramipexole daily) in early- stage PD patients, suboptimally controlled by the DAAdopamine 
agonist. The primary outcome measure was a change in the total UPDRS score value, whereas 
the secondary outcome measures were the UPDRS subscore values and the CGI-I values. Of 
the 328 patients randomized, 321 were included in the analysis of the clinical efficacy. The 
results were presented at the MDS Congress in 2013; significant improvements in the UPDRS 
total score and motor subscore values were reported as compared with the placebo arm. No 
significant differences in the occurrence of adverse events were seen in the two study arms 
and only a few patients needed LDlevodopa rescue therapy. The addition of rasagiline to a 
DAAdopamine agonist significantly improves the motor function with a favorable adverse 
event profile 74. 
7.3 Safinamide as adjunct therapy to LDlevodopa 
The potential antidyskinetic properties of safinamide were explored in clinical trials on PD 
patients suffering from LID. A total of 26 patients were enrolled in a Phase II, double-blind, 
placebo-controlled, parallel-group, dose- escalation trial (Safinamide-LID, NCT01113320). 
The primary outcome measure was the maximum reduction in Unified Dyskinesia Rating 
Score (UDysRS) compared to the baseline. Secondary end- points were the total on and off 
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times as evaluated by the patient diaries and the changes in the UPDRS scale and subscale 
scores and in the CGIclinical global impression 75. 
Study 016 (NCT01187966) and its extension study (Study 018, NCT01286935) evaluated the 
short- and the long-term safety and efficacy of safinamide as add-on therapy to LDlevodopa 
in patients with mid- to- late -stage PD. The 24-month data were presented in 2011 at the 
poster session of the AAN meeting 76. In Study 016, 669 patients with idiopathic PD on a 
stable dose of LDlevodopa therapy were randomized to receive 50 mg/day of safinamide (223 
patients), 100 mg/day of safinamide (224 patients) or placebo (222 patients) daily for 6 
months. The 6-month treatment with safinamide (50 or 100 mg/day) significantly improved 
the motor function, increased the average duration of the on time with no dyskinesia or with 
minor dyskinesia, and decreased the average duration of the off time relative to the placebo. 
Patients who completed the 24-week trial could continue the treatment in the extension study 
(544 patients). Changes in the LDlevodopa dose, and treatment with other PD medication 
except a MAO-B inhibitor, were allowed. The primary end- point was the degree of 
improvement in the Dyskinesia Rating Scale (DRS) scores during the on time as compared 
with the baseline value. At 2 years, the differences seen in the DRS scores for the 50 mg/day 
and the 100 mg/day safinamide groups were not significant, but the post-hoc analysis of the 
100 mg/day safinamide subgroup with severe dyskinesia (DRS scores > 4 at baseline) 
demonstrated a significant improvement in the DRS scores (p = 0.03). Patient diary analysis 
showed that the improvement reported at 6 months was still present after 2 years of therapy 
too. An increase in the daily on time with no/minor dyskinesia and a decrease in the daily off 
time were reported. Overall, the improvement was greater in the daily 100 mg/day safinamide 
group for the motor scores, ADL scores and clinical status. These patients were more likely to 
achieve a reduced LDlevodopa dose than were the patients from the other groups. There were 
few drop-outs, and no safety concerns emerged 76,77,78,79. 
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The SETTLE trial (NCT00627640) evaluated the efficacy and safety of two different doses of 
safinamide (50 –and 100 mg) as compared with placebo as add-on therapy to a stable dose of 
LDlevodopa and other anti-Pparkinson drugs (DAAs, anticholinergics, amantadine and/or 
COMT inhibitors) over 24 weeks in 549 subjects with advanced PD. The principal end- point 
was the increase in mean on time without troublesome dyskinesia, as recorded in the patient 
diaries. A significant benefit of both doses of safinamide over placebo was revealed, with a 
significant improvement of >more than 1 h in the on time as reported by the patient diaries 
and the caregiver and a 30% or more improvement in the motor symptoms (p = 0.018). 
Benefits were observed in the off time, in the quality of life measures (39-Item Parkinson’s 
Disease Questionnaire [PDQ-39] and EQ[r5]-5D), and in the CGIclinical global impression of 
severity and change, and also in the off time after the morning dose of LDlevodopa. The onset 
of the effect was rapid: improvements in both the on time and the off time were observed from 
week 2 onward. Tolerability was good and; 484 patients completed the trial. No relevant 
changes were detected in vital signs, laboratory results, ECG or ophthalmological 
examinations. Adverse events such as nausea, urinary tract infections, falls, back pain and 
dyskinesia were reported. Transient mild dyskinesia occurred more frequently with 
safinamide, but did not lead to discontinuation of the study. No increase in troublesome 
dyskinesia was observed 80,81. 
An open-label trial (NCT00865579) is currently evaluating the long-term safety and 
tolerability of safinamide in PD patients who have already completed a previous study with 
safinamide. The physical and neurological condition together with other safety parameters, 
such as vital signs, laboratory evaluations, ECG and quality of life measures were compared 
at different visits with the baseline 82. 
7.4 Safinamide for PD-associated cognitive impairment 
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In order to explore the potential benefit of safinamide on cognitive impairment associated 
with PD 103, cognitively impaired, but non-demented PD patients were enrolled in a double-
blind, randomized, placebo-controlled, parallel group Phase II clinical trial (NCT01211587). 
The primary outcome measures were the PD Cognitive Rating Scale and subscale scores, 
DRS-2 and subscale scores, the CGIclinical global impression change in cognitive 
dysfunction, the Grid-Hamilton Depression Rating scale, the PD sleep scale and the apathy 
scale scores 83. 
8. Safety and tolerability issues 
In the clinical studies detailed above, the tolerability proved to be good. The clinical trials 
were accompanied by a drop-out rate of only about 11%. No relevant changes in vital signs, 
laboratory results, ECG or other examinations occurred. Adverse events such as nausea, 
dizziness, falls, somnolence, headache, back pain, urinary tract infections and transient mild 
dyskinesia were reported 73,80,81. 
9. Regulatory affairs 
The results of the SETTLE and MOTION trials were presented at the AAN, MDPD and MDS 
conferences. The Newron Company has started meetings with the European health authorities 
to discuss the results of the preclinical and clinical trials in order to achieve support for the 
registration of safinamide as an add-on therapy to DAAs in early stage PD and to LDlevodopa 
in advanced stage PD. Additional discussions with European health authorities, EMA and 
FDA for European and US approval and the regulatory submission were planned for 
QIV/2013 84. 
10. Conclusions 
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The alfaα-aminoamide derivative safinamide exhibits both a dopaminergic and a non-
dopaminergic mode of action. It is a potent selective and reversible MAO-B inhibitor, a 
sodium-channel antagonist and an inhibitor of glutamate release. Safinamide has a dose-
dependent, dose-proportional and linear favorable pharmacokinetic profile. Its 
biotransformation is extensive. It does not interact with CYP 450. Safinamide is well 
tolerated, with few side- effects. 
Safinamide was investigated in Phase III clinical trials as adjunct therapy to DAAs for 
patients with early stage PD and to LDlevodopa therapy for patients in the mid- to- late -
stages of PD. The results from the MOTION and SETTLE studies confirmed that safinamide 
comprises effective add-on therapy to DAAs in early- stage PD patients and to LDlevodopa in 
mid- to- late -stage PD. Safinamide significantly improved the motor function, as assessed by 
the UPDRS motor score in the MOTION study and improved the motor fluctuation assessed 
by the on time without troublesome dyskinesia in mid- to- late -stage PD patients in the 
SETTLE study. In the Phase III trials, significant improvements in the quality of life, assessed 
by the PDQ-39 test and/or by the EQ-5D scale were seen. The Drug Summary Box 1 presents 
the main characteristics of safinamide. 
11. Expert opinion 
The cause of PD is multifactorial and the pathomechanism of the disease is not completely 
understood. There are many unmet needs of PD patients, such as the suitable treatment of 
many of the non-motor symptoms and a neuroprotective therapy capable of protecting the 
dopaminergic neurons from premature death. LDevodopa still is still the best symptomatic 
treatment available, capable of alleviating the motor symptoms of the disease. The MAO-B 
inhibitors provide a lower symptomatic effect on motor symptoms as compared with 
LDlevodopa. Besides an effect on motor symptoms, the delayed-start studies suggest disease-
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modifying properties of the MAO-B inhibitors. As compared with the other compounds in 
this class of medication, safinamide bears a more favorable pharmacokinetic profile and 
complex pharmacodynamic properties. 
Safinamide is a unique compound in exhibiting a combined non-dopaminergic and 
dopaminergic mode of action. It is a reversible MAO-B inhibitor, with a higher selectivity for 
MAO-B than for MAO-A, this selectivity being greater than in the cases of the other 
compounds available in this class of medications. It also inhibits the voltage-sensitive sodium 
channels and modulates the N-type calcium channels. 
The symptomatic effect of safinamide has not yet been compared with those of other MAO-B 
inhibitors. The MOTION study that investigated safinamide as an add-on therapy to DAAs in 
early stage PD patients revealed positive outcomes in the post-hoc analysis for those patients 
taking 100 mg of safinamide. Rasagiline as add-on therapy to DAAs (ropinirole or 
pramipexole) showed more pronounced outcomes in the ANDANTE study. However, the 
results can not be compared, due to the different inclusion criteria. The results suggest that the 
combination of a DAA with a MAO-B inhibitor delays the need for LDlevodopa. Besides the 
symptomatic effect on the motor function, already confirmed in clinical trials, a tremorolytic, 
an antidyskinetic and presumably a neuroprotective effect could be further explored. Further 
trials are needed to assess the effects of safinamide on LDlevodopa-induced fluctuations and 
dyskinesias as compared with placebo, amantadine and COMT inhibitors. In view of the 
various mechanisms involved in PD pathology, a compound combining favorable effects on 
dopaminergic and non-dopaminergic, glutamatergic neurotransmission might well have 
manifold effects in the treatment of PD. 
The important roles played by glutamate in neurotoxicity and by glutamate antagonists in 
neuroprotection have been demonstrated in several animal models of PD and of other 
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neurodegenerative disorders. Neuroactive kynurenines with an antiglutamatergic effect are 
also investigated in this respect 85,86,87,88,89,90. Safinamide-induced neuroprotection has 
been investigated in animal models (MPTP-treated mice, a rat kainic acid model and a gerbil 
ischemia model) and neuroprotective and neurorescuing effects have been revealed. Further 
research is necessary to investigate the potential neuroprotective effect of safinamide in PD 
patients. 
The place of safinamide in the therapy of PD is yet to be determined. The favorable 
pharmacokinetic and side-effect profile and the possibility that the LDlevodopa dose can be 
reduced when safinamide is added together with the presumed neuroprotective properties 
outlined above, suggest that safinamide is a valuable compound in the treatment of PD. It may 
serve as the first line of add-on therapy to DAA and LDlevodopa in the early- and the mid- to- 
late -stage disease, respectively. 
Box 1. Drug summary. 
Drug name Safinamide 
Phase Pre-registration 
Indication Parkinson’s disease 
Pharmacology description Monoamine oxidase B inhibitor 
Route of administration Oral 
Chemical structure 
 
Pivotal trial(s) 69,70,71,72,73,75,76,77,78,79,80,81,82,83 
Pharmaprojects – copyright to Citeline Drug Intelligence (an Informa business). Readers are 
referred to Pipeline (http://informapipeline.citeline.com) and Citeline 
(http://informa.citeline.com). 
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Table 1. Symptoms of Parkinson’s disease. 
Motor symptoms 
 Bradykinesia/akinesia 
 Hypokinesia 
 Tremor 
 Postural instability 
 Gait disorder 
Non-motor symptoms 
 Neuropsychiatric symptoms 
  Psychosis  
   Hallucinations 
   Delusions/illusions 
  Depression 
  Apathy 
  Fatigue 
  Anxiety 
  Cognitive impairment/dementia 
  Sleep disorders 
   REM sleep behavior disorder 
   RLS 
   Vivid dreaming 
   Insomnia 
   Excessive daytime somnolence 
 Autonomic symptoms 
  Drooling 
  Increased sweating 
  Gastrointestinal dysfunction 
   Delayed gastric emptying 
   Constipation 
  Bladder dysfunction  
   Urgency 
   Frequency 
  Orthostatic hypotension 
  Sexual dysfunction 
 Sensory symptoms 
  Anosmia 
  Pain 
  Paresthesia 
REM: Rapid eye movement, RLS: Restless legs syndrome. 
Table 2. The place of safinamide in the treatment approaches in of Parkinson’s disease. 
Dopaminergic therapy Non-dopaminergic therapy 
Levodopa 
  LCIG therapy 
Anticholinergics 
  Benztropine 
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  Trihexyphenidyl 
  Ethopromazine 
 Antiglutamatergic agents 
  Amantadine 
Surgical approaches 
 Dopamine agonists 
  Pramipexole 
  Ropinirole 
  Apomorphine pump 
 MAO-B inhibitors 
  Rasagiline 
  Selegiline 
  Safinamide 
 DBS 
  Ablative surgery 
  Neural transplantation and gene 
therapy 
Drugs tested for symptomatic, antidyskinetic and neuroprotective properties 
Adenosine A2A receptor antagonists Istradefylline, istradefylline[AuQ7] 
Glutamate antagonists Amantadine, kynurenines, 
safinamide 
Glutamate receptor-related compounds MGluR5 antagonists, MGluR4 
agonists 
Antiepileptic drugs with complex mechanism of action Safinamide, zonisamide, 
levetiracetam 
Vitamins Folic acid, vitamin D 
Antioxidants, scavenger of free radicals, compounds 
acting on mitochondria 
Coenzyme Q10, creatine, inosine, 
vitamin E 
Catecholamine reuptake inhibitor 
 α2-adrenergic receptor antagonists 
 Nicotine receptor agonist 
 Serotonin modulators 
 L-type Ca++ channel blocker 
 
DBS: Deep brain stimulation;, LCIG: Levodopa-carbidopa intraintestinal gel therapy; MAO: 
Monoamine oxidase. 
Table 3. Clinical trials with safinamide. 
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Definition Phase/Ttype Duration 
(months) 
N  S dose 
(mg/day) 
Characteristics Outcome measures Results (where 
available) 
Safety and efficacy 
on motor function 
 (Study 009) 69  
Phase III 
 PC 
3 172  70 
(median) 
Early PD: compared 
to placebo 
Responder rate 
(responders: >more than 
30% improvement in the 
UPDRS motor subscore 
compared to baseline) 
 Decrease in UPDRS 
motor score 
 Safety  
37.5%, versus 21.4% in 
the placebo P group 
  
  
 3.3. 
Efficacy and safety 
 (Study 015, 
NCT00643045) 
70,71 
Phase III 
 PC 
24 -
weeks 
269 150- – 
200 
 50- – 
100 
Early PD: add-on 
therapy to DA 
Change in the UPDRS 
motor scores as compared 
to baseline 
Improvement 
Long-term efficacy 
and safety 
 (Study 017, 
NCT00642889) 
70,71 
Phase III 
 R, DB, PC, 
pre-planned 
12 227 100 
  
  
 200 
Early PD:  
Add-on therapy to a 
single stable dose of 
DA 
 Extension of Study 
015 
The time from baseline to 
intervention  
(intervention: an increase 
in the DA dose, addition 
of another DA, addition 
of LD or other PD 
treatment) or the 
discontinuation due to 
lack of efficacy) 
 Intervention rate 
 UPDRS motor scores 
 Quality of life scores 
 Safety 
With 100 mg S: a delay 
in median time to 
intervention of 9 days 
(post-hoc analysis). The 
difference between the 
two S groups was not 
significant. 
  
 Significantly lower 
compared to P 
improvement 
  
 No difference in the 
occurrence of adverse 
events between the 
active and the placebo 
P groups. 
MOTION Phase III 24 weeks 679 50 Early PD:, add-on Change in mean UPDRS- Significant 
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(NCT00605683) 72   R, DB, PC  100 therapy to a DA section III value 
compared to baseline. 
 Change from baseline in 
the ADL, cognition, 
global clinical status, 
responder rates in motor 
function, health- related 
quality of life 
 Safety 
improvement with 100 
mg S 
  
 Significant 
improvement 
  
  
 S was well tolerated 
Extension study 
(NCT01028586) 73 
 78 weeks 507 50 
 100 
Early PD: add-on 
therapy to DA 
Time to intervention 
 Intervention rate 
 The change in UPDRS 
motor scores, ADL 
scores, the change in 
CGIclinical global 
impression, a change in 
quality of life and 
cognitive measures 
Improvement 
Safinamide-LID 
(NCT01113320) 75 
Phase II 
 DB, PC, 
parallel-
group, dose- 
escalation 
10 -
weeks 
26  Late PD:, 
antidyskinetic effect 
The maximum reduction 
in UDysRS compared to 
baseline.  
 The total on and off time 
as evaluated by the 
patient diaries 
 The change in UPDRS 
scale and subscale values 
 The change in the 
CGIclinical global 
impression 
 
Short-term safety 
and efficacy of S 
 (Study 016, 
Phase III 6 669 50 
 100 
Mid- to- late stage 
PD:  
Aadd-on therapy to 
Motor function 
 The average amount of 
the on time with no 
Significant 
improvement 
 Increased 
  27 
NCT01187966) 76 LD  dyskinesia or with minor 
dyskinesia 
 The average duration of 
the off time compared to 
P 
  
 Decreased 
Long-term safety 
and efficacy of S. 
Extension of Study 
016 
 (Study 018, 
NCT01286935) 
 76,77,78,79.  
Phase III 18 544 50 
 100 
Mid- to- late stage 
PD:  
Aadd-on therapy to 
LD 
The degree of 
improvement in the DRS 
scores during on time 
compared to the baseline 
values 
 pPatient diary analysis 
 dDuration of daily on 
time with no/minor 
dyskinesia 
 Dduration of the daily off 
time 
 Motor scores, ADL 
scores and clinical status 
  
 Safety 
Significant 
improvement in 
patients with severe 
dyskineisia with 100 
mg S (post-hoc 
analysis) 
 Long-term 
improvement 
 Increased 
 Decreased 
 Greater improvement 
in the daily 100 mg/day 
S group. Reduction of 
LD dose possible 
 Few drop-outs and no 
safety concerns 
SETTLE efficacy 
and safety of S 
(NCT00627640) 
80,81 
Phase III 
 PC 
24 weeks 549 50 
 100 
Advanced PD:  
aAdd-on therapy to a 
stable dose of LD 
and other 
antiparkinsonian 
drugs 
Increase in mean on time 
without troublesome 
dyskinesia (patient 
diaries) 
 Motor symptoms 
 Decrease in off- time,  
quality of life measures 
and CGI 
 The off-time after the 
morning dose of LD 
 Tolerability, safety 
Significant 
improvement for both 
doses 
  
 A significant 
improvement of >more 
than 30% or more 
  
  
 Good 
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Long-term safety 
and tolerability of S 
(NCT00865579) 82 
Phase III,  
open-label 
3 -years   PD patients that 
have already 
completed a study 
with S 
The physical and 
neurological condition 
 Other safety parameters 
 Quality of life measures 
 
Cognitive 
impairment 
associated with PD 
(NCT01211587) 83 
Phase II DB, 
PC, R, 
parallel group 
24 -
weeks 
103  Cognitively 
impaired, but non-
demented PD 
patients 
PD Cognitive Rating 
Scale and subscale scores 
 Dementia Rating Scale-2 
and subscale scores 
 The CGIclinical global 
impression, the change in 
cognitive dysfunction 
 Grid-Hamilton 
Depression Rating scale 
 PD sleep scale 
 apathy scale 
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See also text for references. 
ADL: Activities of daily living; CGI: Clinical global impression; DA: Dopamine[r8] agonist; 
DB: Double-blind; DRS: Dyskinesia Rating Scale; LD: Levodopa; LID: Levodopa-induced 
dyskinesia; N: Number of patients enrolled; P: Placebo; PC: Placebo-controlled; PD: 
Parkinson’s disease; R: Randomized; S: Safinamide; UDysRS: Unified Dyskinesia Rating 
Score; UPDRS: Unified Parkinson’s Disease Rating Scale. 
Figure 1. The effect of safinamide in the pathomechanism of PD is shown. Protein 
aggregation, oxidative stress, mitochondrial dysfunction and presumably the glutamate-
induced excitotoxicity are major factors contributing to the pathology of PD. These factors 
cause the loss of pigmented neurons of the substantia nigra pars compacta leading to a 
dopamine-deficient state. The dopamine-deficient state, combined with the involvement of 
other neurotransmitter systems, is responsible for the development of the motor and non-
motor symptoms of the disease. Safinamide improves the dopamine-deficient state through 
MAO-B inhibition (1) and improves the motor symptoms. It also exhibits an 
antiglutamatergic effect (2), which may be beneficial in the treatment of dyskinesia. 
Safinamide might also have a neuroprotective role; it may possibly also lower oxidative stress 
through MAO-B inhibition (3) and exert an anti-excitotoxic effect through glutamate 
inhibition (4). 
PD: Parkinson’s disease; MAO: Monoamine oxidase. 
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